Company / Accounts Receivable
PROTHENA CORP PUBLIC LTD CO Accounts Receivable History
FY2016-FY2023 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Accounts Receivable
$5.2M
FY2023
5-year range
$0 / $5.2M
FY2019-FY2023
Trend
-
vs FY2022
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Accounts Receivable returned to growth in FY2023 after 2 years of decline, reaching $5M.
Based on SEC 10-K filings.
$5M in FY2023 with a 5-year CAGR of +381.2%.
Improved from $15,000 to $5M over the past 3 years.
Accounts Receivable over time
Growth rates
- 3-Year CAGR
- +600.6%
- 5-Year CAGR
- +381.2%
- 10-Year CAGR
- -
Key checks
Key Insights
- 5-year CAGR of +381.2%, indicating consistent growth.
- Lowest accounts receivable in the period was in FY2021.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Accounts ReceivableValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | - | - |
| FY2024 | - | - |
| FY2023 | $5.2M | - |
| FY2022 | - | - |
| FY2021 | $0 | -100.0% |
| FY2020 | $15.0K | -77.9% |
| FY2019 | $68.0K | +3300.0% |
| FY2018 | $2.0K | -99.2% |
| FY2017 | $240.0K | +34.8% |
| FY2016 | $178.0K | -65.0% |
As of FY2023 · SEC 10-K Annual Filings · Updated Jun 28, 2026